 | • レポートコード：MRC2301G191 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、243ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に4,484.62百万ドルであった世界の核医学市場規模が、2022年に4,801.22百万ドルに到達し、2027年まで年平均7.23%で成長して6,820.05百万ドルまで拡大すると予測しています。本レポートは、核医学の世界市場について調べ、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（診断用製品、治療用製品）分析、用途別（骨転移、心臓病、内分泌腫瘍、リンパ腫、その他）分析、種類別（診断、治療）分析、エンドユーザー別（病院・診断センター、研究機関）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、以下の構成でまとめております。また、Bayer AG、Bracco S.p.A.、BWX Technologies, Inc.、Cardinal Health, Inc.、Curium、Eckert & Ziegler Group、Eczacibaşi Monrol Nuclear Products Co.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の核医学市場規模：製品別 - 診断用製品の市場規模 - 治療用製品の市場規模 ・世界の核医学市場規模：用途別 - 骨転移における市場規模 - 心臓病における市場規模 - 内分泌腫瘍における市場規模 - リンパ腫における市場規模 - その他における市場規模 ・世界の核医学市場規模：種類別 - 診断おける市場規模 - 治療における市場規模 ・世界の核医学市場規模：エンドユーザー別 - 病院・診断センターおける市場規模 - 研究機関における市場規模 ・世界の核医学市場規模：地域別 - 南北アメリカの核医学市場規模 アメリカの核医学市場規模 カナダの核医学市場規模 ブラジルの核医学市場規模 … - アジア太平洋の核医学市場規模 日本の核医学市場規模 中国の核医学市場規模 インドの核医学市場規模 韓国の核医学市場規模 台湾の核医学市場規模 … - ヨーロッパ/中東/アフリカの核医学市場規模 イギリスの核医学市場規模 ドイツの核医学市場規模 フランスの核医学市場規模 ロシアの核医学市場規模 … - その他地域の核医学市場規模 ・競争状況 ・企業情報 |
The Global Nuclear Medicine Market size was estimated at USD 4,484.62 million in 2021 and expected to reach USD 4,801.22 million in 2022, and is projected to grow at a CAGR 7.23% to reach USD 6,820.05 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Nuclear Medicine to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Diagnostic Products and Therapeutic Products. The Diagnostic Products is further studied across PET and SPECT. The PET is further studied across F-18 and SR-82/RB-82. The SPECT is further studied across GA-67, I-123, TC-99m, and TL-201. The Therapeutic Products is further studied across Alpha Emitters, Beta Emitters, and Brachytherapy. The Beta Emitters is further studied across I-131, Lu-117, Re-186, SM-153, and Y-90. The Brachytherapy is further studied across Cesium-131, Iodine-125, Iridium-192, and Palladium-103.
Based on Application, the market was studied across Bone Metastasis, Cardiology, Endocrine Tumor, Lymphoma, Oncology, and Thyroid.
Based on Type, the market was studied across Diagnostic and Therapeutic. The Diagnostic is further studied across PET Procedures and SPECT Procedures. The Therapeutic is further studied across Alpha Emitter Procedures, Beta Emitter Procedures, and Brachytherapy Procedures.
Based on End-Users, the market was studied across Hospitals & Diagnostic Centers and Research institutes.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Connecticut, Florida, Illinois, Maryland, Minnesota, New Jersey, New York, Ohio, Pennsylvania, Texas, and Washington. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Nuclear Medicine market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Nuclear Medicine Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Nuclear Medicine Market, including Bayer AG, Bracco S.p.A., BWX Technologies, Inc., Cardinal Health, Inc., Curium, Eckert & Ziegler Group, Eczacibaşi Monrol Nuclear Products Co., GE Healthcare, Institute of Isotopes Co., Ltd., Isotopia Molecular Imaging Limited, Jubilant DraxImage, Inc., Lantheus Holdings, Inc., Nordion, Inc., Northstar Medical Technologies LLC, Novartis AG, NTP Radioisotopes SOC Ltd., NuView Life Sciences, Inc., PharmaLogic Holdings LLC, Shine Medical Technologies, Sinotau Pharmaceuticals Group, and State Atomic Energy Corporation Rosatom.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Nuclear Medicine Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Nuclear Medicine Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Nuclear Medicine Market?
4. What is the competitive strategic window for opportunities in the Global Nuclear Medicine Market?
5. What are the technology trends and regulatory frameworks in the Global Nuclear Medicine Market?
6. What is the market share of the leading vendors in the Global Nuclear Medicine Market?
7. What modes and strategic moves are considered suitable for entering the Global Nuclear Medicine Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising Incidence and Prevalence of Cancer Worldwide
5.1.1.2. Increasing Use of PET and SPECT to Diagnose Heart disease and Neurological Disorders
5.1.1.3. International Organizations’ Initiatives and Awareness Supporting Nuclear Medicine
5.1.2. Restraints
5.1.2.1. Shorter Half-Life of Nuclear Medicine
5.1.3. Opportunities
5.1.3.1. Emerging Popularity of Theranostics in Nuclear Medicine
5.1.3.2. Continuous Product Developments and Advancements in Patented Technologies
5.1.4. Challenges
5.1.4.1. Lack of Knowledge, Training, and Availability of Nuclear Medicine in Developing Countries
5.1.4.2. Limited Availability of Skilled Radiologists and Practitioners Worldwide
5.2. Cumulative Impact of COVID-19
6. Nuclear Medicine Market, by Product
6.1. Introduction
6.2. Diagnostic Products
6.3.1. PET
6.3.2.1. F-18
6.3.2.2. SR-82/RB-82
6.3.2. SPECT
6.3.3.1. GA-67
6.3.3.2. I-123
6.3.3.3. TC-99m
6.3.3.4. TL-201
6.3. Therapeutic Products
6.4.1. Alpha Emitters
6.4.2. Beta Emitters
6.4.3.1. I-131
6.4.3.2. Lu-117
6.4.3.3. Re-186
6.4.3.4. SM-153
6.4.3.5. Y-90
6.4.3. Brachytherapy
6.4.4.1. Cesium-131
6.4.4.2. Iodine-125
6.4.4.3. Iridium-192
6.4.4.4. Palladium-103
7. Nuclear Medicine Market, by Application
7.1. Introduction
7.2. Bone Metastasis
7.3. Cardiology
7.4. Endocrine Tumor
7.5. Lymphoma
7.6. Oncology
7.7. Thyroid
8. Nuclear Medicine Market, by Type
8.1. Introduction
8.2. Diagnostic
8.3.1. PET Procedures
8.3.2. SPECT Procedures
8.3. Therapeutic
8.4.1. Alpha Emitter Procedures
8.4.2. Beta Emitter Procedures
8.4.3. Brachytherapy Procedures
9. Nuclear Medicine Market, by End-Users
9.1. Introduction
9.2. Hospitals & Diagnostic Centers
9.3. Research institutes
10. Americas Nuclear Medicine Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Nuclear Medicine Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Nuclear Medicine Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Bayer AG
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Bracco S.p.A.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. BWX Technologies, Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Cardinal Health, Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Curium
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Eckert & Ziegler Group
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Eczacibaşi Monrol Nuclear Products Co.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. GE Healthcare
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Institute of Isotopes Co., Ltd.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Isotopia Molecular Imaging Limited
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Jubilant DraxImage, Inc.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Lantheus Holdings, Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Nordion, Inc.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Northstar Medical Technologies LLC
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Novartis AG
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. NTP Radioisotopes SOC Ltd.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. NuView Life Sciences, Inc.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. PharmaLogic Holdings LLC
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Shine Medical Technologies
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Sinotau Pharmaceuticals Group
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. State Atomic Energy Corporation Rosatom
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing